Tuesday's winners
DeCode Genetics (DCGN: Research, Estimates) up 7-15/16 to 25-15/16. DeCode, which is dedicated to studying Iceland's genetic heritage, priced 9.6 million shares of its IPO at $18 a share, the top of its expected price range.
Transgenomic (TBIO: Research, Estimates) up 9-1/16 to 24-1/16. Transgenomic priced 4.48 million shares of its IPO at $15 a share, which was higher than its expected price range.
Somnus Medical Technologies (SOMN: Research, Estimates) up 15/16 to 3-7/8. The maker of medical devices to treat upper airway disorders said late Monday that U.S. regulators approved the company's device for reducing enlarged tonsils.
AVAX Technologies (AVXT: Research, Estimates) up 2-3/16 to 11-7/8. The biopharmaceutical firm said it has begun selling a personalized skin cancer vaccine in Australia, the first commercial launch of a custom-made skin cancer vaccine. AVAX said it is exploring options for providing the M-Vax vaccine to patients in Europe. And a trial of M-Vax for melanoma is under way in the United States.
GelTex Pharmaceuticals (GELX: Research, Estimates) up 3-7/8 to 30-3/8. GelTex Pharmaceuticals reported earnings of $16.3 million, or 79 cents a share, on revenue of $24.2 million, compared with a loss of $9.4 million, or 56 cents a share, a year earlier. Analysts expected earnings of 41 cents a share.
DeCode Genetics (DCGN: Research, Estimates) up 7-15/16 to 25-15/16. DeCode, which is dedicated to studying Iceland's genetic heritage, priced 9.6 million shares of its IPO at $18 a share, the top of its expected price range.
Transgenomic (TBIO: Research, Estimates) up 9-1/16 to 24-1/16. Transgenomic priced 4.48 million shares of its IPO at $15 a share, which was higher than its expected price range.
Somnus Medical Technologies (SOMN: Research, Estimates) up 15/16 to 3-7/8. The maker of medical devices to treat upper airway disorders said late Monday that U.S. regulators approved the company's device for reducing enlarged tonsils.
AVAX Technologies (AVXT: Research, Estimates) up 2-3/16 to 11-7/8. The biopharmaceutical firm said it has begun selling a personalized skin cancer vaccine in Australia, the first commercial launch of a custom-made skin cancer vaccine. AVAX said it is exploring options for providing the M-Vax vaccine to patients in Europe. And a trial of M-Vax for melanoma is under way in the United States.
GelTex Pharmaceuticals (GELX: Research, Estimates) up 3-7/8 to 30-3/8. GelTex Pharmaceuticals reported earnings of $16.3 million, or 79 cents a share, on revenue of $24.2 million, compared with a loss of $9.4 million, or 56 cents a share, a year earlier. Analysts expected earnings of 41 cents a share.
